Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Category: Treatment


Type 2 diabetes in adults: management

June 29th 2022

This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications (NICE)

Categories: Management, News, Treatment
Tags: Type 2 Diabetes

Categories: Management, Treatment
Tags: Type 2 Diabetes

Diabetes (type 1 and type 2) in children and young people: diagnosis and management

June 29th 2022

This guideline covers the diagnosis and management of type 1 and type 2 diabetes in children and young people aged under 18. The guideline recommends how to support children and young people and their families and carers to maintain tight control of blood glucose to reduce the long-term risks associated with diabetes (NICE)

Categories: Management, News, Paediatrics, Treatment
Tags: Type 1 Diabetes, Type 2 Diabetes

Categories: Management, Paediatrics, Treatment
Tags: Type 1 Diabetes, Type 2 Diabetes

An Early Assessment of the Real-World Treatment Patterns of Type 2 Diabetes: A Comparison to the 2018 ADA/EASD Consensus Report Recommendations

June 29th 2022

Prevalence of guideline-aligned treatment use in 2019 was low, particularly since many patients fit into multiple risk groups with established treatment benefits (Diabetes Therapy)

Categories: News, Treatment
Tags: Type 2 Diabetes

Categories: Treatment
Tags: Type 2 Diabetes

Newer long-acting insulin prescriptions for patients with type 2 diabetes: prevalence and practice variation in a retrospective cohort study

May 26th 2022

The inter-practice variation in the prescription of newer insulins is large and could only be partially explained by patient- and practice-related differences. This indicates substantial opportunities for improvement (British Journal of General Practice)

Categories: Medication, Treatment
Tags: long-acting, Type 2 Diabetes

Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE Study

April 28th 2022

While the benefit of CGM on TIR among patients with type 2 diabetes treated with basal insulin is apparent across the range of baseline glycemic control, the greatest impact of CGM is in those with the worst baseline glycemic control, particularly among those with HbA1c ≥10% (Diabetes Technology & Therapeutics)

Categories: News, Treatment
Tags: CGM, insulin, Type 2 Diabetes

Categories: Treatment
Tags: CGM, insulin, Type 2 Diabetes

Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?

April 26th 2022

Achievement of sustained virologic response using interferon free, directly acting antivirals-based regimen was associated with significantly lower HbA1c 12 weeks after the end of therapy. The type of treatment used for type 2 diabetes (oral drugs or insulin) did not affect improved glycemic control observed after achieving sustained virologic response (Metabolic Syndrome and Obesity)

Categories: Management, News, Treatment
Tags: Antivirals, Hepatitis C Virus, Type 2 Diabetes

Categories: Management, Treatment
Tags: Antivirals, Hepatitis C Virus, Type 2 Diabetes

Cardiovascular and renal outcomes of initial combination therapy with glucose-lowering agents versus stepwise approach in newly diagnosed or treatment naïve type 2 diabetes: a systematic review and meta-analysis

April 18th 2022

Except for improving cardiometabolic and glycaemic parameters, a limited number of studies characterised by small sample sizes show that initial combination therapy for newly diagnosed T2D may be similar in efficacy and safety to stepwise therapy with respect to cardio-renal outcomes. There is a lack of sufficient evidence to recommend initial combination therapy with glucose-lowering agents in newly diagnosed T2D with the aim of preventing cardio-renal outcomes. Definitive RCTs are warranted (Diabetes, Obesity and Metabolism)

Categories: Medication, News, Treatment
Tags: Type 2 Diabetes

Categories: Medication, Treatment
Tags: Type 2 Diabetes

Current Management of Glycemia in Children with Type 1 Diabetes Mellitus

March 24th 2022

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the authors’ clinical recommendations (NEJM)

Categories: News, Treatment
Tags: Type 1 Diabetes

Categories: Treatment
Tags: Type 1 Diabetes

Incidence and Characteristics of Remission of Type 2 Diabetes in England: A Cohort Study Using the National Diabetes Audit

March 24th 2022

Remission of type 2 diabetes was generally infrequent in routine care settings but may be a reasonable goal for a subset of people who lose a significant amount of weight shortly after diagnosis (Diabetes Care)

Categories: Audits, News, Treatment
Tags: Type 2 Diabetes

Categories: Audits, Treatment
Tags: Type 2 Diabetes

Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD

March 24th 2022

In patients with T2D treated with simvastatin, fenofibrate reduced the composite of HF hospitalizations or cardiovascular mortality, an effect that was seen predominantly in patients with standard background glucose-lowering therapy (Diabetes Care)

Categories: Medication, News, Treatment
Tags: fenofibrate, simvastatin, Type 2 Diabetes

Categories: Medication, Treatment
Tags: fenofibrate, simvastatin, Type 2 Diabetes

Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D)

March 24th 2022

Three-year follow-up of the largest cohort of randomized patients followed to date demonstrates that metabolic/bariatric surgery is more effective and durable than medical/lifestyle intervention in remission of type 2 diabetes, including among individuals with class 1 obesity, for whom surgery is not widely used (Diabetes Care)

Categories: Bariatric, News, Treatment
Tags: ARMMS-T2D, Type 2 Diabetes

Categories: Bariatric, Treatment
Tags: ARMMS-T2D, Type 2 Diabetes

The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review

March 21st 2022

The ‘SGLT2i Prescribing Tool for T2DM Management’, previously published by the Steering Committee, has been updated to reflect the latest evidence and is provided in the Supplementary Materials to help support clinicians delivering T2DM care (Diabetes Therapy)

Categories: News, Treatment
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Treatment
Tags: SGLT2 inhibitors, Type 2 Diabetes

Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes

March 14th 2022

In an 8-week outpatient study, addition of 5 mg daily empagliflozin to commercially available AID or PLGS systems significantly improved daytime glucose control in individuals with T1D, without increased hypoglycemia risk. However, the risk of ketosis and ketoacidosis remains (Diabetes Technology and Therapeutics)

Categories: Medication, News, Treatment
Tags: Empagliflozin

Categories: Medication, Treatment
Tags: Empagliflozin

Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus

February 10th 2022

CGM is superior to SMBG in improving glycaemic control among individuals with type 1 diabetes in the community, especially in those with uncontrolled glycaemia (Diabetologia)

Categories: Management, News, Treatment
Tags: CGM, Type 1 Diabetes

Categories: Management, Treatment
Tags: CGM, Type 1 Diabetes

Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations

February 4th 2022

The use of a personalized approach in the management of people with T2D can reduce the cost and failure associated with the algorithmic “one-size-fits-all” approach, to anticipate disease progression, improve the response to diabetes pharmacotherapy and reduce the incidence of diabetes-associated complications (Metabolic Syndrome and Obesity)

Categories: Medication, News, Treatment
Tags: Type 2 Diabetes

Categories: Medication, Treatment
Tags: Type 2 Diabetes

Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial)

January 31st 2022

The effect of intra-lymphatic injections of GAD-alum had decreased after 30 months. Good responders showed a specific immune response. Administration of a fourth booster dose after 31.5 months was safe, and there was no decline in C-peptide observed during the 12-month follow-up (Acta Diabetologica)

Categories: News, Treatment
Tags: GAD-alum, Type 1 Diabetes

Categories: Treatment
Tags: GAD-alum, Type 1 Diabetes

ADA/EASD Precision Medicine in Diabetes Initiative: An International Perspective and Future Vision for Precision Medicine in Diabetes

January 21st 2022

Interest in the potential for precision medicine in the prevention, treatment, and ongoing management of diabetes continues to grow across many of the most important stakeholder groups, including people with diabetes (Diabetes Care)

Categories: Medication, News, Treatment
Tags: ADA

Categories: Medication, Treatment
Tags: ADA

Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes

January 20th 2022

A hybrid closed-loop system significantly improved glycemic control in very young children with type 1 diabetes, without increasing the time spent in hypoglycemia (NEJM)

Categories: News, Paediatrics, Treatment
Tags: closed-loop, Type 1 Diabetes

Categories: Paediatrics, Treatment
Tags: closed-loop, Type 1 Diabetes

Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors

January 19th 2022

Our study demonstrated high rates of residual cardio-kidney outcomes and treatment failure in patients with DKD treated with SGLT2is. Patients with high baseline CV risk and the presence of certain conditions, such as atrial fibrillation, PVD, and heart failure, were at higher risk for cardio-kidney events (BMC Medicine)

Categories: Cardiovascular, Nephropathy, News, Treatment
Tags: SGLT2 inhibitors, Type 2 Diabetes

Categories: Cardiovascular, Nephropathy, Treatment
Tags: SGLT2 inhibitors, Type 2 Diabetes

Switching from Neutral Protamine Hagedorn (NPH) Insulin to Insulin Glargine 300 U/mL in Older and Younger Patients with Type 2 Diabetes: A Post Hoc Analysis of a Multicenter, Prospective, Observational Study

January 17th 2022

The switch from NPH insulin to Gla-300 improved glycemic control in older patients with T2D and in those with a longer disease duration. Older patients with T2D and those with a longer disease duration benefited even more from the switch to Gla-300 than younger patients and those with a shorter disease duration, with significantly greater reductions in the risk of hypoglycemia (Diabetes Therapy)

Categories: Medication, News, Treatment
Tags: insulin, Type 2 Diabetes

Categories: Medication, Treatment
Tags: insulin, Type 2 Diabetes
  • 1
  • 2
  • 3
  • …
  • 25
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

Novo NordiskAstraZenecaBoehringer IngelheimNapp Diabetes

Silver Sponsors

About Ascensia Diabetes CareAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership